The Fraxis platforms offer any combination of fractional CO2 laser, microneedle fractional RF and lotus gynolaser to treat numerous indications – from skin resurfacing to vaginal rejuvenation.
Fraxis, distributed in Australia by Cryomed, is a single machine with multiple technologies and countless applications.
With the capability to unite three proven technologies in cosmetic medicine, Fraxis has a flexible treatment modality for an ambit of patient concerns – from scars to wrinkles to full facial resurfacing and hyperhidrosis – all in the one device. Extending this further, the Fraxis platforms now offer the LOTUS GynoLaser for vaginal rejuvenation and urinary incontinence.
Fraxis now with Lotus Gynolaser
Having a Fraxis platform in your clinic means it’s also possible to provide vaginal rejuvenation treatments – for both vaginal relaxation syndrome (VRS) and vaginal atrophy – with only the purchase of the new LOTUS handpiece.
This latest handpiece attachment transforms the Fraxis platform into a gynaecology laser to treat vaginal laxity, atrophy, discomfort and urinary incontinence.
CO2 laser is a proven method for improving the symptoms associated with VRS and urinary incontinence. It delivers a thermal effect on the mucosa, helping to regenerate the underlying connective tissue. Treatment time is relatively short (20 minutes) and the patient’s downtime is minimal.
The Lotus GynoLaser difference lies in its ease of use and the way it delivers the treatment. Unlike other vaginal rejuvenation lasers, the Lotus GynoLaser has an in-built clicking support fixture, which means it automatically rolls the pillar every 45 degrees. Therefore the practitioner does not have to manually move the handpiece, resulting in greater comfort for the patient.
It is also equipped with the i-Slide, a patented comfort slide that hovers over the treatment probe for greater ease of operation and rotation, ensuring maximum control and patient comfort.
Lotus GynoLaser delivers 100–150 micrometre fractional laser light in micro pulses. The pulsing energy contributes to the treatment’s safety profile, and the wavelength is optimum for collagen regeneration.
Marriage of convenience: fractional CO2 laser with microneedling RF
The Fraxis Duo is also distributed by Cryomed. It is the first of its kind of combination therapy with fractional CO2 laser and Secret RF (a non-insulated microneedle factional radiofrequency system) to hit Australia, and has been shown to achieve effective results in treating scars, photoageing and striae distensae on the face and body.
Combining the two technologies means both superficial and deeper heating coagulation can be achieved. The CO2 fractional laser enables intense superficial heating stimulation while the microneedle fractional RF provides higher volumetric heating and deeper heat diffusion. This caters to a wide spectrum of medical and cosmetic indications, including acne scarring, wrinkles, skin laxity and pigmentation.
On a device that’s sure to see a lot of use, the Fraxis Duo is intuitive and easy to use. A 22.8cm colour touchscreen with a user-friendly interface is designed to complement the intelligently designed arm, which minimises fatigue and allows ease of use in both the Fraxis and Secret RF modalities. Combining the two technologies optimises results for certain indications that require both superficial and deeper heating coagulation.
From a patient’s perspective, Fraxis and Fraxis Duo allow the treatment of all skin types for numerous indications, including acne scars, wrinkles, pigmentation, skin laxity, and poor skin tone and texture. Both superficial and deep stimulation is achieved in the one device, increasing effectiveness, saving time and reducing side effects.
Safety and comfort are also maximised by delivering energy to the target skin layer without damaging the surrounding tissue.
Clinical effectiveness of Fraxis duo
A 2013 study investigated the efficacy and safety of combination therapy.
The research involved 30 female participants with moderate to severe striae distensae, aged between the ages of 21 to 51, with Fitzpatrick skin type IV.
Patients were divided into three groups: fractional CO2 laser only (n = 10), microneedle RF only (n = 10) and combination (n = 10).
Results were gauged using a visual analogue scale (range 1-4). The mean clinical improvement score, as rated by the dermatologist, was 2.2 in the fractional CO2 laser group and 1.8 in the micro needle RF group. Both these scores differed significantly to 3.4 in the combination group.
A skin biopsy was also conducted, which revealed a thickened epidermis and a clear increase in the number of collagen fibres in the sites treated with the combined approach. This was seen alongside a greater expression of transforming growth factor-1 and stratifin in the skin.
For more information, call 1300 346 448 or visit www.cryomed.com.au